SecBot SecBot

AYTU

AYTU BIOPHARMA, INC
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001385818 Biotech & Drug Discovery
$1.93 +0.03 (+1.58%)
Oct 26 4:00 PM ET · prev $1.90
Market cap
$21.5M
Nano cap
Consensus
Buy
89% Buy or better · 9 analysts
Median target
$7.00
+263% · range $7.00–15.00
Next earnings
Nov 16
in 21 days · EPS est. −$0.18
1 year
−12.7%
from $2.21 · Oct 27
30 days
−11.1%
from $2.17
52-week range
$1.90–2.90
−33% from high · low Oct 23
Avg volume 20D
24.6K
Sep 30 spike 67.7K
Short interest
345.2K
≈3.2% of shares · +10.8%
Days to cover
4.7
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 16, 2026
Strongest NEUTRAL Aytu BioPharma filed its definitive proxy statement for the 2026 annual meeting, seeking shareholder…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 4 added (0 new), 0 trimmed or exited.

  • AnalystsBULLISH

    8 of 9 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.020 → −$0.180 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +10.8% to 345.2K shares. 4.7 days to cover, ≈3.2% of shares.

  • TrendDOWNTREND

    10% below its 50-day average. New closing low $1.90 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
CITADEL ADVISORS LLCADD49,414$106.2K
NORTHERN TRUST CORPADD27,925$60.0K
UBS Group AGADD2,377$5.1K
ROYAL BANK OF CANADADOUBLED378$1.0K
GEODE CAPITAL MANAGEMENT, LLCADD92,636$252.9K
UBS Group AGTRIM1,663$4.5K
TWO SIGMA INVESTMENTS, LPADD107,133$278.5K
MORGAN STANLEYTRIM125$325.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 89% rate it Buy or better
Strong Buy2Buy6Hold1Sell0Strong Sell0
12-month targets · 3 analysts

Price is below the lowest target. Median implies +263%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 30, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy
Jun 11, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jul 28, 2026
DOCKERY CARL
Director
AWARD10,000 sh
Jul 28, 2026
LIU VIVIAN H
Director
AWARD10,000 sh
Jul 28, 2026
JAIN ABHINAV
Director
AWARD10,000 sh
Jul 28, 2026
Selhorn Ryan J
Chief Financial Officer
AWARD25,000 sh
Jul 28, 2026
Donofrio John Jr.
Director
AWARD10,000 sh
Jul 28, 2026
Disbrow Jarrett
Chief Business Officer
AWARD15,000 sh
Jul 28, 2026
PYSZCZYMUKA GREG
Chief Commercial Officer
AWARD20,000 sh
Jul 28, 2026
Disbrow Joshua R.
Chief Executive Officer
AWARD30,000 sh

Earnings setup

Estimates
Nov 16
reports in 21 days
−$0.18
EPS estimate, this quarter
−800%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.18-$0.26–-$0.10-800.0%$13.3M
Next Q-$0.14-$0.18–-$0.09-775.0%$15.3M
Current FY-$0.36-$0.57–-$0.16-386.7%$67.9M
Next FY$0.15$0.14–$0.17—$86.9M

Short side

FINRA· Sep 30, 2026
345,229
shares short
+10.8%
vs prior settlement
4.7
days to cover
≈3.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Aytu BioPharma filed its definitive proxy statement for the 2026 annual meeting, seeking shareholder approval for five…
DEF 14A — Impact 4/10
Sep 22, 2026 SEC
Aytu BioPharma reported fiscal Q4 2026 results with net revenue of $16.1M (+6.4% YoY), driven by $3.9M in EXXUA…
8-K — Impact 6/10
Sep 22, 2026 Earnings calendar
AYTU Q4 2026 Earnings After Market Close — 2026-09-22
Jul 28, 2026 Insider
DOCKERY CARL was granted 10,000 shares
Director
Jul 28, 2026 Insider
LIU VIVIAN H was granted 10,000 shares
Director
Jul 28, 2026 Insider
JAIN ABHINAV was granted 10,000 shares
Director
Jul 14, 2026 Event
EXXUA
BOXED WARNING WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicida
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — ADD
49,414 shares ($106.2K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 16, 2026
Earnings date
AYTU Q1 2027 Earnings Scheduled — 2026-11-16
Recent
Sep 22, 2026
Earnings date
AYTU Q4 2026 Earnings After Market Close — 2026-09-22
Jul 14, 2026
FDA
EXXUA
BOXED WARNING WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young ad
Jul 14, 2026
FDA
EXXUA
BOXED WARNING WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young ad
May 13, 2026
Earnings date
AYTU Q3 2026 Earnings Scheduled — 2026-05-13

SecBot reports

4 filings · 1 bullish · 1 bearish · 2 neutral
All AYTU filing & press-release reports (4)